This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Myomo, Inc. (MYO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Myomo, Inc. (MYO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) Rides on New Product Portfolio, SaaS Growth
by Zacks Equity Research
Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.
QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe
by Zacks Equity Research
QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.
ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.
Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark
by Zacks Equity Research
Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.
Align (ALGN) Rides on Volume Expansion Despite Cost Concerns
by Zacks Equity Research
We are upbeat about Align's (ALGN) consistent uptrend in Invisalign volumes across all geographies.
Here's Why You Should Hold on to Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on its strong segmental and international results in Q1.
Teleflex's Bipolar Temporary Pacing Guidewire Gets FDA Nod
by Zacks Equity Research
Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.
Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.
Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block
by Zacks Equity Research
Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.
Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0.00% and -53.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GNC Holdings Inks Retail Partnership Deal to Grow in Brazil
by Zacks Equity Research
We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.
Innovation Aids Genomic Health, Merger Procedure on Track
by Zacks Equity Research
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has various favorable factors to maintain the current high.
Will Myomo, Inc. (MYO) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. (MYO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 15.00% and -3.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -5.00% and -25.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -10.53% and 1.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?